How to achieve confidence in drug discovery and development: Managing risk (from a reductionist to a holistic approach)

ChemMedChem

Volumn 4, Issue 6, 2009, Pages 923-933

  Bakker, Annette ^a   Caricasole, Andrea ^a   Gaviraghi, Giovanni ^a   Pollio, Giuseppe ^a   Robertson, Graeme ^a   Terstappen, Georg C ^a   Salerno, Massimiliano ^a   Tunici, Patrizia ^a  

^a Siena Biotech SpA   (Italy)

Author keywords

Drug development; Drug discovery; Drug targets; Medicinal chemistry

Indexed keywords

ALOSETRON; AMYLOID BETA PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN INHIBITOR; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ICG 001; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6 INHIBITOR; MATRIX METALLOPROTEINASE; NOTCH RECEPTOR; PROTEIN KINASE B; PROTEIN P53; SEROTONIN AGONIST; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; DECISION MAKING; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; GLIOBLASTOMA; GROWTH INHIBITION; HOLISTIC APPROACH; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; MOLECULAR MODEL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REACTION OPTIMIZATION; REDUCTIONIST APPROACH; REVIEW; RISK MANAGEMENT; STATISTICS; STRUCTURE ACTIVITY RELATION; TRANSCRIPTOMICS; VALIDATION PROCESS;

CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; MODELS, ANIMAL; MODELS, CHEMICAL; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 67049134843     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900056     Document Type: Review

References (35)

1. USFDA Critical Path Whitepaper, March 2004: Challenge and Opportunity on the Critical Path to New Medical Products, http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.pdf (Last accessed April 14, 2009).
2. a) M. Austen, C. Dohrmann, Drug Discovery Today 2005, 10, 275-282;
3. b) A. Schrattenholz, V. Soskić, Curr. Med. Chem. 2008, 15, 1520-1528.
4. G. Griffioen, IDrugs 2007, 10, 259-263.
5. C. J. Zheng, L. Y. Han, C. W. Yap, Z. L. Ji, Z. W. Cao, Y. Z. Chen, Pharmacol. Rev. 2006, 58, 259-279.
6. M. L. Billingsley, Pharmacology 2008, 82, 239-244.
7. G. Pollio, R. Roncarati, T. Seredenina, G. C. Terstappen, A. Caricasole, J. Neurosci. Methods 2008, 172, 34-37.
8. G. Pollio, J. J. Hoozemans, C. A. Andersen, R. Roncarati, M. C. Rosi, E. S. van Haastert, T. Seredenina, D. Diamanti, S. Gotta, A. Fiorentini, L. Magnoni, R. Raggiaschi, A. J. Rozemuller, F. Casamenti, A. Caricasole, G. C. Terstappen, Neurobiol. Dis. 2008, 31, 145-158.
9. H. P. Fischer, Biotechnol. Annu. Rev. 2005, 11, 1-68.
10. B. Stransky, J. Barrera, L. Ohno-Machado, S. J. De Souza, J. Bioinf. Comput. Biol. 2007, 5, 977-986.
11. S. K. Pavelic, N. Saban, Expert Opin. Drug Discovery 2007, 2, 431-436.
12. a) R. Kaddurah-Daouk, K. R. Krishnan, Neuropsychopharmacology 2009, 34, 173-186;
13. b) A. H. Harrill, I. Rusyn, Expert Opin. Drug Metab. Toxicol. 2008, 4, 1379-1389.
14. J. A. Bilello, Curr. Mol. Med. 2005, 5, 39-52.
15. M. H. V. Van Regenmortel, EMBO Rep. 2004, 5, 1016-1020.
16. J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander, T. R. Golub, Science 2006, 313, 1929-1935.
17. D. R. Rhodes, S. Kalyana-Sundaram, S. A. Tomlins, V. Mahavisno, N. Kasper, R. Varambally, T. R. Barrette, D. Ghosh, S. Varambally, A. M. Chinnaiyan, Neoplasia 2007, 9, 443-454.
18. PriceWaterhouseCoopers Publications: Pharma 2020: The Vision, http://www.pwc.com/extweb/pwcpublications.nsf/docid/ 91BF330647FFA402852572F2005ECC22 (Last accessed April 14, 2009).
19. a) R. Miller, W. Ewy, B. W. Corrigan, D. Ouellet, D. Hermann, K. G. Kowalski, P. Lockwood, J. R. Koup, S. Donevan, A. El-Kattan, C. S. Li, J. L. Werth, D. E. Feltner, R. L. Lalonde, J. Pharmacokinet. Pharmacodyn. 2005, 32, 185-197;
20. b) J. Y. Chien, S. Friedrich, M. A. Heathman, D. P. deAlwis, and V. Sinha, AAPS J. 2005, 7, E544-E559.
21. U. S. Eggert, A. A. Kiger, C. Richter, Z. E. Perlman, N. Perrimon, T. J. Mitchison, C. M. Field, PLoSBiol. 2004, 2, 2135-2143.
22. G. C. Terstappen, C. Schluepen, R. Raggiaschi, G. Gaviraghi, Nat. Rev. Drug Discovery 2007, 6, 891-903.
23. D. A. Reardon, P. Y. Wen, Oncologist 2006, 11, 152-164.
24. M. D. Taylor, X. Zhang, L. Liu, C. C. Hui, T. G. Mainprize, S. W. Scherer, B. Wainwright, D. Hogg, J. T. Rutka, Oncogene 2004, 23, 4577-4583.
25. E. T. Valera, H. R. Machado, C. A. Scrideli, A. K. Lucio-Eterovic, L. G. Tone, Curr. Pharm. Biotechnol. 2007, 8, 105-113.
26. S. Das, M. Srikanth, J. A. Kessler, Nat. Clin. Pract. Neurol. 2008, 4, 427-435.
27. A. Kikuchi, H. Yamamoto, S. Kishida, Cell. Signalling 2007, 19, 659-671.
28. M. Katoh, M. Katoh, Clin. Cancer Res. 2007, 13, 4042-4045.
29. J. M. Yu, E. S. Jun, J. S. Jung, S. Y. Suh, J. Y. Han, J. Y. Kim, K. W. Kim, J. S. Jung, Cancer Lett. 2007, 257, 172-181.
30. K. S. Carmon, D. S. Loose, Mol. Cancer Res. 2008, 6, 1017-1028.
31. M. Katoh, Stem Cell Rev. 2007, 3, 30-38.
32. S. H. Yang, T. Andl, V. Grachtchouk, A. Wang, J. Liu, L. J. Syu, J. Ferris, T. S. Wang, A. B. Glick, S. E. Millar, A. A. Dlugosz, Nat. Genet. 2008, 40, 1130-1135.
33. K. H. Emami, C. Nguyen, H. Ma, D. H. Kim, K. W. Jeong, M. Eguchi, R. T. Moon, J. L. Teo, H. Y. Kim, S. H. Moon, J. R. Ha, M. Kahn, Proc. Natl. Acad. Sci. USA 2004, 101, 12682-12687.
34. a) M. Dragunow, Nat. Rev. Neurosci. 2008, 9, 779-788;
35. b) M. Bickle, IDrugs 2008, 11, 822-826.